When did Gilead Sciences report Q1 2025 earnings?

Gilead Sciences (GILD) reported Q1 2025 earnings on April 24, 2025 after market close.

What were Gilead Sciences's Q1 2025 revenue and EPS?

Gilead Sciences reported revenue of $6.7B and diluted EPS of $1.81 for Q1 2025.

Did Gilead Sciences beat estimates in Q1 2025?

Revenue missed the consensus estimate of $6.8B by $143.9M. EPS beat the consensus estimate of $1.78 by $0.03.

How did Gilead Sciences's Q1 2025 results compare year-over-year?

Compared to the same quarter a year prior, revenue declined 0.3% from $6.7B a year earlier.

Where can I find Gilead Sciences's Q1 2025 SEC filings?

You can read the 10-Q periodic report (0000882095-25-000012) directly on SEC EDGAR. The filing index links above go to sec.gov.

Gilead Sciences GILD Q1 2025 earnings

Reported April 24, 2025 · After market close

Revenue$6.7BMiss by $143.9M Diluted EPS$1.81Beat by $0.03

Revenue estimate$6.8B

EPS estimate$1.78

Next report

Aug 6, 2026 (in a month)

Revenue estimate$7.4B

EPS estimate-$7.20

Financials

Q1 2025

Income statement

See full

Revenue$6.7B-0.3%

Gross profit$5.1B-0.1%

Operating income$2.2B+152%

Net income$1.3B+132%

EPS (diluted)$1.04+131%

Balance sheet

See full

Cash & equivalents$7.9B+68.0%

Total debt$25.0B-1.0%

Total equity$19.2B+9.3%

Total assets$56.4B+0.3%

Cash flow

See full

Operating cash flow$1.8B-20.8%

CapEx$104.0M-1.0%

Free cash flow$1.7B-21.8%

Valuation & ratios

Q1 2025

Valuation

See full

Market cap$139.69B+53.1%

Enterprise value$156.71B+40.3%

P/E23.4×-165×

P/S4.9×+1.5×

Profitability

See full

Gross margin78.3%+2.5pp

Operating margin28.6%+22.9pp

Net margin20.8%+19.0pp

FCF margin34.3%+5.5pp

Returns & leverage

See full

Return on equity32.5%+30.0pp

Debt / equity1.3×-0.1×

Current ratio1.4×+0.3×

Segments

By product

See full

Biktarvy$3.2B+6.9%

Descovy$586.0M+37.6%

Yescarta$386.0M+1.6%

Genvoya$364.0M-9.7%

Sofosbuvir/Velpatasvir$346.0M-14.6%

By geography

See full

Europe$1.1B-6.5%

Rest of World$915.0M+2.3%

Versus estimates

Revenue

Q1 2026$7.0BBeat by $46.6M Q4 2025$7.9BBeat by $234.6M Q3 2025$7.8BBeat by $323.6M Q2 2025$7.1BBeat by $99.5M

Q1 2025$6.7BMiss by $143.9M

Q4 2024$7.6BBeat by $416.5M

Diluted EPS

Q1 2026$2.03Beat by $0.12 Q4 2025$1.86Beat by $0.05 Q3 2025$2.47Beat by $0.34 Q2 2025$2.01Beat by $0.05

Q1 2025$1.81Beat by $0.03

Q4 2024$1.90Beat by $0.16

Ask the moment Gilead Sciences reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Gilead Sciences report Q1 2025 earnings?: Gilead Sciences (GILD) reported Q1 2025 earnings on April 24, 2025 after market close.
What were Gilead Sciences's Q1 2025 revenue and EPS?: Gilead Sciences reported revenue of $6.7B and diluted EPS of $1.81 for Q1 2025.
Did Gilead Sciences beat estimates in Q1 2025?: Revenue missed the consensus estimate of $6.8B by $143.9M. EPS beat the consensus estimate of $1.78 by $0.03.
How did Gilead Sciences's Q1 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue declined 0.3% from $6.7B a year earlier.
Where can I find Gilead Sciences's Q1 2025 SEC filings?: You can read the 10-Q periodic report (0000882095-25-000012) directly on SEC EDGAR. The filing index links above go to sec.gov.